Cefaloram

Cefaloram

SCHEMBL612836

CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3ccccc3)[C@H]2SC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 7/20 1.00
CTDSP1 Q9GZU7 2/20 0.80
MAPT P10636 7/20 0.77
NR1I2 O75469 3/20 0.77
HPGD P15428 2/20 0.77
DNMT1 P26358 1/20 0.77
SLC22A6 Q4U2R8 1/20 0.77
SLC22A8 Q8TCC7 1/20 0.77
SLC22A11 Q9NSA0 1/20 0.77
L3MBTL1 Q9Y468 3/20 0.75
ESR1 P03372 1/20 0.71
PGR P06401 1/20 0.71
PTGS2 P35354 1/20 0.71
KDR P35968 1/20 0.71
PTGS1 P23219 1/20 0.71
MAPK1 P28482 1/20 0.70
HSD17B10 Q99714 3/20 0.64
POLB P06746 3/20 0.64
CYP3A4 P08684 2/20 0.64
PKM P14618 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cefaloram SCHEMBL612837 1.00 TDP1 (1.00) TDP1CTDSP1MAPTNR1I2HPGD
Cefaloram SCHEMBL11057775 1.00 TDP1 (1.00) TDP1CTDSP1MAPTNR1I2HPGD
Cefaloram SCHEMBL11057780 1.00 TDP1 (1.00) TDP1CTDSP1MAPTNR1I2HPGD
Cefaloram SCHEMBL27274373 1.00 TDP1 (1.00) TDP1CTDSP1MAPTNR1I2HPGD
Cefaloram SCHEMBL10428695 1.00 TDP1 (1.00) TDP1CTDSP1MAPTNR1I2HPGD
Cefaloram SCHEMBL8722133 0.99 TDP1 (0.98) TDP1CTDSP1MAPTNR1I2HPGD
Cefaloram SCHEMBL1133618 0.95 TDP1 (0.90) TDP1CTDSP1MAPTNR1I2HPGD
SCHEMBL22015085 0.94 TDP1 (0.89) TDP1CTDSP1MAPTNR1I2HPGD
SCHEMBL11566566 0.93 TDP1 (0.87) TDP1CTDSP1MAPTNR1I2HPGD
SCHEMBL11566449 0.92 TDP1 (0.86) TDP1CTDSP1MAPTNR1I2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12251417-B2 Antimicrobial compounds from the genus Delftia MINISTRY OF HEALTH, STATE OF ISRAEL (IL) 2025-03-18 US claimed
US-20230398194-A1 METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCE THERIVA BIOLOGICS INC (US) 2023-12-14 US claimed
CN-117015613-A Detection of beta-lactamase activity 原子能和代替能源委员会 2023-11-07 CN claimed
US-20220348645-A1 CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2022-11-03 US claimed
EP-3963087-A1 IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT Illumina Inc (US) 2022-03-09 EP claimed
WO-2021159176-A1 ANTIMICROBIAL COMPOUNDS THE UNIVERSITY OF WOLLONGONG (AU) 2021-08-19 WO claimed
WO-2021067628-A2 CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2021-04-08 WO claimed
US-20200370098-A1 Compositions and Methods for Identifying Secretory Antibody-Bound Microbes HATTERAS VENTURE PARTNERS V, LP 2020-11-26 US claimed
WO-2020223259-A1 IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT ILLUMINA, INC. (US) 2020-11-05 WO claimed
CN-107827911-B 7-phenylacetylaminocephalosporanic acid composite crystal and preparation method thereof 华北制药股份有限公司 2020-03-24 CN claimed
EP-0317484-A2 N,N'-carboxyl-bis-(4-ethyl-2,3-dioxo)-piperazine, process for the preparation thereof and use thereof GEMA S.A. (ES) 1989-05-24 EP claimed
US-4797394-A 6-(1-carbamoyl-1-hydroxymethyl)penicillanic acid derivatives PFIZER INC. (US) 1989-01-10 US claimed
EP-0084925-B1 6-AMINOALKYLPENICILLANIC ACID 1,1-DIOXIDES AND DERIVATIVES AS BETA-LACTAMASE INHIBITORS PFIZER INC. (US) 1986-04-09 EP claimed
US-4503040-A 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors PFIZER INC. (US) 1985-03-05 US claimed
EP-0034924-B1 PROCESS FOR PREPARING 3-IODOMETHYL CEPHALOSPORINS ELI LILLY AND COMPANY (US) 1984-07-04 EP claimed
US-4452796-A ANTIBIOTICS PFIZER INC. (US) 1984-06-05 US claimed
US-4427678-A 6-Aminomethylpenicillanic acid 1,1-dioxide derivatives as beta-lactamase inhibitors PFIZER INC. (US) 1984-01-24 US claimed
EP-0084925-A1 6-Aminoalkylpenicillanic acid 1,1-dioxides and derivatives as beta-lactamase inhibitors PFIZER INC. (US) 1983-08-03 EP claimed
US-4144391-A REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE ELI LILLY AND COMPANY (US) 1979-03-13 US claimed
US-4013650-A PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS CIBA-GEIGY CORPORATION (US) 1977-03-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12251417-B2 Antimicrobial compounds from the genus Delftia TUFM, DPM1, MGAM TDP1 1925/4885CTDSP1 3334/4885MAPT 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.